Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Mitsui Seiyaku describes sigma-opioid antagonist

April 26, 1996

Sigma-opioid ligands from ADIR

April 26, 1996

U.S. government claims new antipsychotic compositions

April 26, 1996

IRI-695 for anxiety and depression

April 26, 1996

TAD-93 in preclinical studies for anxiety

April 26, 1996

New 5-HT1D antagonists from Pierre Fabre

April 26, 1996

SKB reports 5-HT2B/2C antagonists for CNS indications

April 26, 1996

Adolor aims to advance ADL-2-1294 into clinical trials

April 26, 1996

BMS antimigraine agent poised to enter clinical trials

April 26, 1996

NPC-18688 displays long-lasting antihyperalgesic effects in rodents

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 8, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...